Storia in 3 fonti

AstraZeneca to take rights to Dizal's lung cancer pill for $600M upfront

AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

AstraZeneca licenses worldwide rights to Dizal's lung cancer pill Zegfrovy for $600M upfront, plus up to $900M in milestones and royalties.

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is